Vertex Pharmaceuticals (Canada)

Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2

Michael P. Clark, Mark W. Ledeboer, Ioana Davies et al. · Journal of Medicinal Chemistry · 2014 · 207 citations · Full text

Influenza Pb2, Medicinal Chemistry, Medicine +13

Methicillin‐Resistant <i>Staphylococcus aureus</i>: A Public Health Issue with Economic Consequences

Mireille Goetghebeur, Pierre‐Alexandre Landry, Donald Han et al. · Canadian Journal of Infectious Diseases and Medical Microbiology · 2006 · 113 citations · Full text

Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia

Hélène David, Benoît Haelewyn, Christophe Rouillon et al. · The FASEB Journal · 2007 · 104 citations

Anesthetic Mechanism, Pharmacotherapy, Anesthetic Gas Xenon +21

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

Immunology, Immunologic Mechanism, Janus Tyrosine Kinases +16

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers

Erik S. Linklater, Elizabeth A. Tovar, Curt J. Essenburg et al. · Oncotarget · 2016 · 77 citations · Full text

Breast Oncology, Kinase Inhibitors, Cancer Biology +16